Psychopharmacology of anorexia nervosa, bulimia nervosa, and binge eating disorder

Clinical Handbook of Eating Disorders: An Integrated Approach

Volumn , Issue , 2004, Pages 491-510

  Steinglass, Joanna E ^a   Timothy Walsh, B ^a  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85083175428     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (95)

1. American Psychiatric Association. Practice guidelines for the treatment of patients with eating disorders (Revision). Am J Psychiatry (Supplement) 2000; 157(1):l-39.
2. Lacey J, Crisp AH. Hunger, food intake and weight: the impact of clomipramine on a refeeding anorexia nervosa population. Postgrad J Med 1980; 56(suppl 1): 79-95.
3. Biederman J, Herzog D, Rivinus T, et al. Amitriptyline in the treatment of anorexia nervosa: a double-blind, placebo-controlled study. J Clin Psychopharmacol 1985; 5, 10-16.
4. Halmi K, Eckert E, LaDu T, Cohen J. Anorexia nervosa: treatment efficacy of cyproheptadine and amitriptyline. Arch Gen Psychiatry 1986; 43:177-181.
5. Wilens T, Biederman J, Baldessarini R, et al. Cardiovascular effects of therapeutic doses of tricyclic antidepressants in children and adolescents. J Am Acad Child Adolesc Psychiatry 1996; 35:1491-1501.
6. Ferguson J. Treatment of an anorexia nervosa patient with flouxetine. Am J Psychiatry 1987; 144:1239.
7. Gwirtsman H, Guze B, Yager J, Gainsley B. Fluoxetine treatment of anorexia nervosa: an open clinical trial. J Clin Psychiatry 1990; 51:1378-1382.
8. Attia E, Haiman C, Walsh T, Flater S. Does fluoxetine augment the inpatient treatment of anorexia nervosa? Am J Psychiatry April 1998; 155(4):548-551.
9. Strober M, Pataki C, Freeman R, DeAntonio M. No effect of adjunctive fluoxetine on eating behavior or weight phobia during the inpatient treatment of anorexia nervosa: an historical case-control study. J Child Adol Psychopharmacol 1999; 9(3):195-201.
10. Kaye W, Nagata T, Weltzin T, et al. Double-blind placebo-controlled administration of fluoxetine in restricting and restricting-purging-type anorexia nervosa. Biol Psychiatry 2001; 49:644-652.
11. Strober M, Freeman R, DeAntonio M, Lampert C, Diamond J. Does adjunctive fluoxetine influence the post-hospital course of anorexia nervosa? A 24-month prospective, longitudinal follow-up and comparison with historical controls. Psychopharmacol Bull 1997; 33:425-431.
12. Kaye W, Ebert M, Raleigh Mea. Abnormalities in CNS monoamine metabolism in anorexia nervosa. Arch Gen Psychiatry 1984; 41:350-355.
13. Kaye W, Gendall K, Strober M. Serotonin neuronal function and selective serotonin reuptake inhibitor treatment in anorexia and bulimia nervosa. Biol Psychiatry 1998; 44:825-838.
14. Attia E, Mayer L, Killory E. Medication response in the treatment of patients with anorexia nervosa. J Psychiat Pract 2001; 7:157-162.
15. Dally P, Sargant W. A new treatment of anorexia nervosa. British Medical Journal 1960; 1:1770-1773.
16. Vandereycken W, Pierloot R. Pimozide combined with behavior therapy in the short term treatment of anorexia nervosa. Acta Psychiatr Scand 1982; 66:445-450.
17. Vandereycken W. Neuroleptics in the short-term treatment of anoreixia nervosa: a double-blind placebo-controlled study with sulpiride. Br J Psychiatry 1984; 144:288-292.
18. Jensen V, Mejlhede A. Anorexia nervosa: treatment with olanzapine. Br J Psychiatry July 2000; 177:87.
19. La Via M, Gray N, Kaye W. Case reports of olanzapine treatment of anorexia nervosa. Intl J Eat Disord 2000; 27:363-366.
20. Mehler C, Wewetzer C, Schulze U, Warnke A, Theisen F, Dittmann R. Olanzapine in children and adolescents with chronic anorexia nervosa: a study of five cases. Eur Child Adol Psychiatry 2001; 10:151-157.
21. Vigersky R, Loriaux D. The effect of cyproheptadine in anorexia nervosa: a doubleblind trial. In: Vigersky R, ed. Anorexia Nervosa. New York: Raven Press, 1977: 349-356.
22. Goldberg S, Halmi K, Eckert E, Casper R, Dacis J. Cyproheptadine in anorexia nervosa. Br J Psychiatry 1979; 134:67-70.
23. Stacher G, Kiss A, Wiesnagrotzki S, et al. Oesophageal and gastric motility disorders in patients categorized as having primary anorexia nervosa. Gut 1986; 27:1120-1126.
24. Domstad P, Shis W, Humphries L, DeLand F, Digenis G. Radionuclide gastric emptying studies in patients with anorexia nervosa. J Nucl Med 1987; 28:816-819.
25. Modolsfsky H, Jeuniewic N. Preliminary report of metoclopramine in anorexia nervosa. In: Vigersky R, ed. Anorexia Nervosa. New York: Raven Press, 1977: 373-375.
26. Stacher G, Abatzi-Wenzel T, Wiesnagrotzki S, Bergmann H, Schneider C, Gaupmann G. Gastric emptying, body weight and symptoms in primary anorexia nervosa: long term effects of cisapride. Br J Psychiatry 1993; 162:398-402.
27. Szmukler G, Young G, Miller G, Lichtenstein M, Binns D. A controlled trial of cisapride in anorexia nervosa. Int J Eat Disord 1995; 17:345-357.
28. Kaye W. Opioid antagonist drugs in the treatment of anorexia nervosa. In: Garfinkel P, Garner D, eds. The Role of Drug Treatments for Eating Disorders. New York: Brunner/Mazel, 1987:150-160.
29. Marrazi M, Bacon J, Kinzie J, et al. Naltrexone use in the treatment of anorexia nervosa and bulimia nervosa. Int J Clin Psychopharmacol 1995; 10:163-172.
30. Katz R, Keen C, Litt I, Hurley L, Kellams-Harrison K, Glader L. Zinc deficiency in anorexia nervosa. J Adol Health Care 1987; 8:400-406.
31. Lask B, Fosson A, Rolfe U, Thomas S. Zinc deficiency and childhood-onset anorexia nervosa. J Clin Psychiatry 1993; 54:63-66.
32. Birmingham C, Goldner E, Bakan R. Controlled trial of zinc supplementaion in anorexia nervosa. Int J Eat Disord 1994; 15:251-255.
33. Safai-Kutti S. Oral zinc supplementation in anorexia nervosa. Acta Psychiatr Scand 1990; 361:814-817.
34. Gross H, Ebert M, Faden V, Goldberg S, Nee L, Kaye W. A double-blind controlled trial of lithium carbonate in primary anorexia nervosa. J Clin Psychopharmacol 1981; 1:376-381.
35. Gross H, Ebert M, Faden V, et al. A double-blind trial of delta9-tetrahydrocannacinol in primary anorexia nervosa. J Clin Psychopharmacol 1983; 3:165-171.
36. Kiblanski A, Biller B, Schoenfeld D, Herzog D, Saxe V. The effects of estrogen administration on trabecular bone loss in young women with anorexia nervosa. J Clin Endocrinol Metab 1995; 80:898-904.
37. Kotler L, Devlin M, Walsh BT. Eating disorders and related disturbances. 2002; 410-430.
38. Walsh B, Devlin M. The pharmacologic treatment of eating disorders. Psychiatr Clin North Am 1992; 15:149-160.
39. Mitchell J, Raymond N, Specke S. A review ofthe controlled trials of pharmacotherapy and psychotherapy in the treatment of bulimia nervosa. Int J Eat Disord 1993; 14:229-247.
40. Agras W, Dorian B, Kirkley B, et al. Imipramine in the treatment of bulimia: a double-blind controlled study. Int J Eat Disord 1987; 6:29-38.
41. Barlow J, Bloluin J, Blouin A, Perez E. Treatment of bulimia with desipramine: a double-blind crossover study. Can J Psychiatry 1988; 33:129-133.
42. Hughes P, Wells L, Cunningham C, et al. Treating bulimia with desipramine: a double-blind, placebo-controlled trial. Arch Gen Psychiatry 1986; 43:182-186.
43. Mitchell J, Groat R. A placebo-controlled, double-blind trial of amitriptyline in bulimia. J Clin Psychopharmacol 1984; 4:186-193.
44. Pope HJ, Hudson J, Jonas Jea. Bulimia treated with imipramine: a placebocontrolled, double-blind study. Am J Psychiatry 1983; 140:554-558.
45. Walsh B, Hadigan C, Devlin M, Gladis M, Roose S. Long-term outcome of antidepressant treatment for bulimia nervosa. Am J Psychiatry 1991; 148:1206-1212.
46. Kennedy S, Piran N, Warsh J, et al. A trial of isocarbozacid in the treatment of bulimia nervosa. J Clin Psychopharmacol 1988; 8:391-396.
47. Walsh B, Stewart J, Roose S, Gladis M, Glassman A. Treatment of bulimia with phenelzine: a double-blind placebo controlled study. Arch Gen Psychiatry 1984; 41:1105-1109.
48. Walsh B, Gladis M, Roose Sea. Phenelzine vs placebo in 50 patients with bulimia. Arch Gen Psychiatry 1988; 45:471-475.
49. Fluoxetine Bulima Nervosa Collaborative (FBNC) Study Group. Fluoxetine in the treatment of bulimia nervosa: a multi-center, double-blind, placebo-controlled trial. Arch Gen Psychiatry 1992; 49:139-147.
50. Goldstein D, Wilson M, Thompson Vea. Fluoxetine Bulimia Nervosa Collaborative Study Group. Long term fluoxetine treatment of bulimia nervosa. Br J Psychiatry 1995; 166:660-666.
51. Pope HJ, Keck PE Jr, McElroy S, et al. A placebo-controlled study of trazodone in bulimia nervosa. J Clin Psychopharmacol 1989; 9:159-254.
52. Roberts J, Lydiard R. Sertraline in the treament of bulimia nervosa [letter]. Am J Psychiatry 1993; 150:1753.
53. Ayuso-Guttierrez J, Palazon M, Ayuso-Mateos J. Open trial of fluvoxamine in the treatment of bulimia nervosa. Int J Eat Disord 1994; 15:245-249.
54. Spigset O, Pleym H. Case report of successful treatment of bulimia nervosa with fluvoxamine [letter]. Pharmacopsychiatry 1991; 24:180.
55. Fichter M, Kruger R, Rief W, Hollan R, Dohne J. Fluvoxamine in prevention of relapse in bulimia nervosa: effects of eating specific psychophathology. J Clin Psychopharmacol 1996; 16:9-18.
56. Romano S, Halmi K, Sarkar N, Koke S, Lee J. A placebo-controlled study of fluoxetine in continued treatment of bulimia nervosa after successful acute fluoxetine treatment. Am J Psychiatry 2002; 159:96-102.
57. Horne R, Ferguson J, Pope HJ, et al. Treatment of bulimia with buproprion: a multicenter controlled trial. J Clin Psychiatry 1988; 49:262-266.
58. Walsh B. Psychopharmacologic treatment of bulimia nervosa. J Clin Psychiatry 1991; 52(10, suppl):34-48.
59. Bacaltchuk J, Hay P, Mari J. Antidepressants versus placebo for the treatment of bulimia nervosa: a systematic review. Aust N Z J Psychiatry 2000; 34:310-317.
60. Hsu L, Clement L, Santhuse R, Ju E. Treatment of bulimia nervosa with lithium carbonate, a controlled study. J Nerv Ment Dis 1991; 179:351-355.
61. Leitenberg H, Rosen J, Wolf J, Vara L, Detzwwer M, Srebnik D. Comparison of cognitive-behavior therapy and desipramine in the treatment of bulimia nervosa. Behav Res Ther 1994; 32:37-45.
62. Mitchell J, Pyle R, Hatsukami D, Pomeroy C, Zimmerman R. A comparison study of antidepressants and structured group therapy in the treatment of bulimia nervosa. Arch Gen Psychiatry 1990; 47:149-157.
63. Wermuth B, Davis K, Hollister L, Stunkard A. Phenytoin treatment of the bingeeating syndrome. Am J Psychiatry 1977; 134:1249-1253.
64. Kaplan A, Garfinkel P, Darby P, Garner D. Carbamazepine in the treatment of bulimia. Am J Psychiatry 1983; 140:1225-1226.
65. Knable M. Topiramate for bulimia nervosa in epilepsy. Am J Psychiatry 2001; 158:322-323.
66. Hoopes S, Reimherr F, Kamin M, Karvois D, Rosenthal N, Karim R. Topiramate treatment of bulimia nervosa. Scientific and Clinical Report Session 2: Eating Disorders. Philadelphia, PA: American Psychiatric Association, May 2002 (Annual meeting).
67. Liebowitz S. The role of serotonin in eating disorders. Drugs 1990; 39(suppl 3): 33-48.
68. Krahn D, Mitchell J. Use of L-tryptophan in treating bulimia (letter). Am J Psychiatry 1985; 142, 1130.
69. Blouin A, Blouin J, Bushnik T, Zuro C, Mulder E. Treatment of bulimia with fenfluramine and desipramine. J Clin Psychopharmacol 1988; 8:261-269.
70. Fahy T, Eisler I, Russell G. A placebo-controlled trial of d-fenfluramine in bulimia nervosa. Br J Psychiatry 1993; 162:597-603.
71. Russel G, Checkley S, Feldman J, Eisler I. A controlled trial of d-fenfluramine in bulimia nervosa. Clin Neuropharmacol 1988; 11:8146-8159.
72. Faris P, Kim S, Meller W, et al. Effect of ondansetron, a 5-HT3 receptor antagonist, on the dynamic association between bulimic behaviors and pain thresholds. Pain 1998; 77:297-303.
73. Faris P, Kim S, Meller W, et al. Effect of decreasing afferent vagal activity with ondansetron on symptoms of bulimia nervosa: a randomised, double-blind trial. Lancet 2000; 355:792-797.
74. Jonas J, Gold M. Treatment of antidepressant-resistant bulimia with naltrexone. In J Psychiatry Med 1987; 16:305-309.
75. Mitchell J, Christenson G, Jennings J, et al. A placebo-controlled, double-blind crossover study of naltrexone hydrochloride in outpatients with normal-weight bulimia. J Clin Psychopharmacol 1989; 9:94-97.
76. Keel PK, Mitchell J, Davis T, Crow S. Long-term impact of treatment in women diagnosed with bulimia nervosa. Int J Eat Disord 2000; 31:151-158.
77. Agras W, Arnow B, Schneider J, et al. Pharmacologic and cognitivebehavioral treatment for bulimia nervosa: a controlled comparison. Am J Psychiatry 1992; 49:82-87.
78. Walsh B, Wilson G, Loeb K, et al. Medication and psychotherapy in the treatment of bulimia nervosa. Am J Psychiatry 1997; 154:523-531.
79. Goldbloom D, Olmstead M, Davis R, et al. A randomized controlled trial of fluoxetine and cognitive behavioral therapy for bulimia nervosa: short term outcome. Behav Res Ther 1997; 35:803-811.
80. Beumont P, Russell J, Touyz S, et al. Intensive nutritional counseling in bulimia nervosa: a role for supplementation with fluoxetine? Aust N Z J Psychiatry 1997; 31:514-524.
81. Bacaltchuk J, Trefiglio R, Oliveira I, Hay P, Lima M, Mari J. Combination of antidepressants and psychological treatments for bulimia nervosa: a systematic review. Acta Psychiatr Scand June 26 1999; 101:256-267.
82. McCann U, Agras W. Successful treatment of nonpurging bulimia nervosa with desipramine: a double-blind, placebo-controlled study. Am J Psychiatry 1990; 147:1509-1513.
83. Laederach-Hofman K, Graf C, Lippuner K, Lederer S, Michel R, Schneider M. Imipramine and diet counseling with psychological support in the treatment of obese binge-eaters: a randomized, placebo-controlled double-blind study. Int J Eat Disord 1999; 26:231-244.
84. Hudson J, McElroy S, Raymond N, et al. Fluvoxamine in the treatment of bingeeating disorder: a multicenter placebo-controlled, double-blind trial. Am J Psychiatry 1998; 155:1756-1762.
85. McElroy S, Casuto L, Nelson E, et al. Placebo-controlled trial of sertraline in the treatment of binge eating disorder. Am J Psychiatry 2000; 157:1004-1006.
86. Shapira N, Goldsmith T, McElroy S. Treatment of binge-eating disorder with topiramate: a clinical case series. J Clin Psychiatry 2000; 61:368-372.
87. Appolinario J, Coutinho W, Fontenelle L. Topiramate for binge-eating disorder. Am J Psychiatry 2001; 158:967-968.
88. McElroy S, Arnold L, Shapira N, et al. Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial. Am J Psychiatry February 2003; 160(2):255-261.
89. Alger S, Schwalberg M, Bigaouette J, et al. Effect of a tricyclic antidepressant and opiate antagonist on binge-eating in normal weight bulimic and obese bingeeating subjects. Am J Clin Nutr 1991; 53:865-871.
90. Stunkard A, Berkowits R, Tanrikut C, Reiss E, Young L. d-Fenfluramine treatment of binge eating disorder. Am J Psychiatry 1996; 153:1455-1459.
91. Appolonario JC, Godoy-Matos A, Fontenelle LF, et al. An open trial of sibutramine in obese patients with binge eating disorder. J Clin Psychiatry 2002; 63:28-30.
92. Agras W, Telch C, Arnow B, et al. Weight loss, cognitive-behavioral, and desipramine treatments in binge eating disorder. An additive design. Behav Ther 1994; 25:225-238.
93. Devlin M, Goldfein J, Carino J, Wolk S. Open treatment of overweight binge eaters with phentermine and fluoxetine as an adjunct to cognitive-behavioral therapy. Int J Eat Disord 2000; 28:325-332.
94. Marcus M, Wing R, Ewing L, Kern E, Gooding W, McDermott M. A doubleblind, placebo controlled trial of fluoxetine plus behavior modification in the treatment of obese binge eaters and non-binge eaters. Am J Psychiatry 1990; 147:876-881.
95. Grilo C, Masheb R, Heninger G, Wilson G. Controlled comparison of cognitive behavorial therapy and fluoxetine for binge eating disorder. In: Mitchell J, ed. Scientific II Session. International Conference on Eating Disorders. BED and Obesity. Boston: Academy for Eating Disorders, April 28, 2002.